Clinical and prognostic value of metabolic disorders in non-alcoholic fatty liver disease

Cover Page

Cite item

Full Text

Abstract

Aim. A comprehensive assessment of metabolic parameters in patients with non-alcoholic fatty liver disease and based on them the development of prognostic criteria for the development of liver fibrosis.

Materials and methods. 288 patients with non-alcoholic fatty liver disease at the stage of steatosis were examined. The patients underwent ultrasound examination of the hepatobiliary system using the SONIX OP apparatus (Canada), the FibroMax test, and liver elastography using the AIXPLORER apparatus (France). The parameters of anthropometry, lipid spectrum, protein and pigment metabolism, cytolysis, cholestasis, bilirubin, insulin in the blood serum were evaluated. The methods of statistical forecasting are used.

Results. The clinical picture in patients with non-alcoholic fatty liver disease at the stage of steatosis was nonspecific and was due to the presence of concomitant diseases of the digestive system and the cardiovascular system. A kettle index of up to 30 was observed in 26.5% of patients, from 30 to 34.9 in 37.5%, from 35 to 39.9 in 29.7% of patients, more than 40 in 6.3% of patients. The results obtained during the biochemical analysis of blood serum indicate the presence of atherogenic dyslipidemia, an increase in the level of total protein, bilirubin, transaminases, gamma-glutamyl transpeptidase and a decrease in alkaline phosphatase in relation to the control group. Against the background of elevated glucose levels, an increase in basal insulin levels was observed (p=0.001). HOMA-IR insulin resistance was increased in patients (p=0.01). When analyzing the results of the study, the main prognostic criteria (body mass index and atherogenicity coefficient) in the diagnosis of non-alcoholic fatty liver disease in the stage of steatosis with high specificity (97.8%) and sensitivity (96.2%) were determined. In determining the risk of progression of non-alcoholic fatty liver disease into liver fibrosis, the model of prognostic criteria included insulin and triglycerides with a specificity of 93.8% and a sensitivity of 85.7%.

Conclusion. Among many variable factors, we have identified the main prognostic criteria that are highly likely to diagnose non-alcoholic fatty liver disease at an early stage and determine the risk of progression to liver fibrosis.

About the authors

Ya. M. Vakhrushev

Izhevsk State Medical Academy

Email: anna.lukashevich.89@mail.ru
ORCID iD: 0000-0003-4634-2658

д.м.н., проф., зав. каф.

Russian Federation, Izhevsk

E. V. Suchkova

Izhevsk State Medical Academy

Email: anna.lukashevich.89@mail.ru
ORCID iD: 0000-0001-7968-4916

к.м.н., ассистент каф.

Russian Federation, Izhevsk

А. Р. Lukashevich

Izhevsk State Medical Academy

Author for correspondence.
Email: anna.lukashevich.89@mail.ru
ORCID iD: 0000-0001-9424-6316

к.м.н., ассистент каф.

Russian Federation, Ижевск

References

  1. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюдения DIREG 01903). Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014;24(4):32-8 [Drapkina OM, Ivashkin VT. Epidemiological features of non-alcoholic fatty liver disease in Russia (results of an open multicenter prospective observation study DIREG 01903). Ros. zhurnal gastroenterologii, gepatologii, koloproktologii. 2014;24(4):32-8 (In Russ.)]
  2. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования Direg 2. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31-41 [Ivashkin VT, Drapkina OM, Mayev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Ros. zhurnal gastroenterologii, gepatologii, koloproktologii. 2015;25(6):31-41 (In Russ.)].
  3. Трухан Д.И. Неалкогольная жировая болезнь печени в практике врача «первого контакта». Клин. перспективы гастроэнтерологии, гепатологии. 2012;1:3-9 [Truhan DI. Nonalcoholic fatty liver disease in the practice of “first contact” physician. Klin. perspektivy gastroenterologii, gepatologii. 2012;1:3-9 (In Russ.)].
  4. Вахрушев Я.М., Лукашевич А.П., Сучкова Е.В. Ассоциация избыточного интестинального бактериального роста и заболеваний гепатобилиарного тракта. Архивъ внутренней медицины. 2019;9(1):64-9 [Vakhrushev YaM, Lukashevich AP, Suchkova EV. Association of intestinal bacterial overgrowth and diseases of hepatobiary tract. Arkhiv vnutrenney meditsiny. 2019;9(1):64-9 [In Russ.)]. doi: 10.20514/2226-6704-2019-9-1-64-69
  5. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103-9. doi: 10.1016/0016-5085(94)90235-6
  6. Полунина Т.Е. Жировая инфильтрация печени. Эффективная фармакотерапия. Гастроэнтерология. 2014;3:32-40 [Polunina TE. Fatty Liver. Effektivnaya farmakoterapiya. Gastroenterologiya. 2014;3:32-40 (In Russ.)].
  7. Blachier M, Leleu H, Peck-Radozavljevic M, et al. The burden of liver disease in Europe: A review of available epidemiological data. Hepatology. 2013;58:593-608. doi: 10.1016/j.jhep.2012.12.005
  8. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-73. doi: 10.1001/jama.2015.5370
  9. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344-53. doi: 10.1002/hep.24376
  10. Лазебник Л.Б., Звенигородская Л.А. Метаболический синдром и органы пищеварения. М.: Анахарсис, 2009 [Lazebnik LB, Zvenigorodskaya LA. Metabolic syndrome and digestive organs. Moscow: Anaharsis, 2009 (In Russ.)]
  11. Liew PL, Lee YC, Lin YC, et al. Comparison of artificial neural networks with logistic regression in prediction of gallbladder disease among obese patient. Digestive and Liver Disease. 2007;23:356-62. doi: 10.1016/j.dld.2007.01.003
  12. Mccullough AJ. The epidemiology and risk factors of NASH. Hepatology. 2013;58(5):1644-54. doi: 10.1002/9780470987438.ch3
  13. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Hepatology. 2010;53:372-84. doi: 10.1016/j.jhep.2010.04.008
  14. Волкова Н.И., Поркшеян М.И. Неалкогольная жировая болезнь печени: что мы знаем и что предстоит узнать. Терапевтический архив. 2017;2(89):91-8 [Volkova NI, Porksheyan MI. Nonalcoholic fatty liver disease: What do we know and what will we have to learn? Therapeutic Archive. 2017;2(89):91-8 (In Russ.)]. doi: 10.17116/terarkh201789291-98
  15. Драпкина О.М., Костюкевич М.В. Статины и риск развития сахарного диабета. Сахарный диабет. 2012;2:77-82 [Drapkina OM, Kostyukevich MV. Statin use and risk of diabetes mellitus. Sakharnyy diabet. 2012;2:77-82 (In Russ.)]. doi: 10.14341/2072-0351-5523
  16. Мельниченко Г.А., Елисеева А.Ю., Маевская М.В. Распространенность неалкогольной жировой болезни печени при ожирении и ее взаимосвязь с факторами риска сердечно-сосудистых заболеваний и сахарного диабета 2-го типа. Рос. журн. гастроэнтерологии, гепатологии, колопрокологии. 2012;2:45-52 [Melnichenko GA, Yeliseyeva AYu, Mayevskaya MV. Prevalence of non-alcoholic fatty liver disease in obesity and its relationship with risk factors for cardiovascular diseases and type 2 diabetes mellitus. Ros. zhurnal gastroenterologii, gepatologii, koloproktologii. 2012;2:45-52 (In Russ.)]
  17. Савельев В.С., Петухов В.А., Яблоков Е.Г. Липидный дистресс-синдром в хирургии. Бюл. эксперим. биологии и медицины. 1999;127(6):604-11 [Savelyev VS, Petukhov VA, Yablokov YeG. Lipid distress syndrome in surgery. Bulletin of Experimental Biology and Medicine. 1999;127(6):604-11 (In Russ.)]
  18. Подымова С.Д. Болезни печени. М.: Медицина, 2005 [Podymova SD. Liver diseases. Moscow: Meditsina, 2005 (In Russ.)]
  19. Филиппович Ю.Б. Основы биохимии. 4-е изд., перераб. и доп. М.: Агар, 1999 [Filippovich Yu.B. Fundamentals of Biochemistry. 4th ed., rev. and add. Moscow: Agar, 1999 (In Russ.)]
  20. Tsochatzis EA. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther. 2011;2(1):1-5. doi: 10.4292/wjgpt.v2.i1.1

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies